These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series. Kwon IJ; Kim SE; Kim SC; Lee SE J Dermatol; 2024 Mar; 51(3):441-447. PubMed ID: 38115742 [TBL] [Abstract][Full Text] [Related]
8. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes. Guttmann-Gruber C; Tockner B; Scharler C; Hüttner C; Common JE; Tay ASL; Denil SLIJ; Klausegger A; Trost A; Breitenbach J; Schnitzhofer P; Hofbauer P; Wolkersdorfer M; Diem A; Laimer M; Strunk D; Bauer JW; Reichelt J; Lang R; Piñón Hofbauer J Sci Rep; 2018 Sep; 8(1):13430. PubMed ID: 30194425 [TBL] [Abstract][Full Text] [Related]
9. Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin. Aala WJF; Hou PC; Hong YK; Lin YC; Lee YR; Tu WT; Papanikolaou M; Benzian-Olsson N; Onoufriadis A; I Chen Harn H; Hwang DY; Cheng SM; Lu K; Chen PC; McGrath JA; Hsu CK Br J Dermatol; 2024 Jul; 191(2):252-260. PubMed ID: 38477474 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Kragballe K; Steijlen PM; Ibsen HH; van de Kerkhof PC; Esmann J; Sorensen LH; Axelsen MB Arch Dermatol; 1995 May; 131(5):556-60. PubMed ID: 7741542 [TBL] [Abstract][Full Text] [Related]
12. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics associated with increased wound size in patients with recessive dystrophic epidermolysis bullosa. Solis DC; Gorell ES; Teng C; Barriga M; Nazaroff J; Li S; Subica A; Lu Y; Marinkovich MP; Tang JY Pediatr Dermatol; 2021 May; 38(3):704-706. PubMed ID: 33749033 [TBL] [Abstract][Full Text] [Related]
14. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa. Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF; Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. Dubertret L; Wallach D; Souteyrand P; Perussel M; Kalis B; Meynadier J; Chevrant-Breton J; Beylot C; Bazex JA; Jurgensen HJ J Am Acad Dermatol; 1992 Dec; 27(6 Pt 1):983-8. PubMed ID: 1479106 [TBL] [Abstract][Full Text] [Related]
17. Dystrophic epidermolysis bullosa pruriginosa is not associated with frequent FLG gene mutations. Schumann H; Has C; Kohlhase J; Bruckner-Tuderman L Br J Dermatol; 2008 Aug; 159(2):464-9. PubMed ID: 18565177 [TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial. Chiou AS; Choi S; Barriga M; Dutt-Singkh Y; Solis DC; Nazaroff J; Bailey-Healy I; Li S; Shu K; Joing M; Kwon P; Tang JY J Am Acad Dermatol; 2020 Jun; 82(6):1415-1421. PubMed ID: 31541747 [TBL] [Abstract][Full Text] [Related]
19. Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): Results of a pilot trial. Fine JD; Manes B; Frangoul H J Am Acad Dermatol; 2015 Jul; 73(1):56-61. PubMed ID: 25956659 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial. Lara-Corrales I; Parkin PC; Stephens D; Hamilton J; Koren G; Weinstein M; Sibbald RG; Pope E J Am Acad Dermatol; 2012 Feb; 66(2):264-70. PubMed ID: 22153787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]